Abstract
The introduction of erythropoiesis-stimulating agents(ESA), such as recombinant human erythropoietin (EPO)has allowed effective treatment of anaemia in patients withchronic kidney disease (CKD). However, the optimal tar-get level of haemoglobin is debated and many patients areresistant to ESA.Hepcidin is a recently discovered low-molecular-weightprotein that plays an important role in iron metabolism.Hepcidin may be relevant in CKD and explain the often-observed disbalance in iron metabolism and the resistanceto ESA. As such hepcidin could become an important toolto predict ESA responsiveness and to guide treatment withESA and intravenous iron. In addition, hepcidin has thepotential to become a target of treatment. In this review wesummarize the pathophysiology of hepcidin and discuss itspotential relevance for patients with CKD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
